UPLOAD Filing
Rein Therapeutics, Inc.
Date: Sept. 4, 2025 · CIK: 0001420565 · Accession: 0000000000-25-009562
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-290016
Letter
Re: Rein Therapeutics, Inc. Registration Statement on Form S-1 Filed September 3, 2025 File No. 333-290016 Dear Brian Windsor:
September 4, 2025
Brian Windsor Chief Executive Officer Rein Therapeutics, Inc. 12407 N. Mopac Expy., Suite 250 #390 Austin, TX 78758
This is to advise you that we have not reviewed and will not review your registration statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Joshua Gorsky at 202-551-7836 with any questions.
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Daniel K. Donahue
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> September 4, 2025 Brian Windsor Chief Executive Officer Rein Therapeutics, Inc. 12407 N. Mopac Expy., Suite 250 #390 Austin, TX 78758 Re: Rein Therapeutics, Inc. Registration Statement on Form S-1 Filed September 3, 2025 File No. 333-290016 Dear Brian Windsor: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Joshua Gorsky at 202-551-7836 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Daniel K. Donahue </TEXT> </DOCUMENT>